A new study from the artificial intelligence (AI)-driven health technology company, nference, and the Mayo Clinic, finds no links among any of the three COVID-19 vaccines and cerebral venous sinus thrombosis, the rare brain clots known as CVST.
Now, the Mayo Clinic and nference confirm that there is no statistically significant link between CVST and those vaccines, as well as other non-COVID shots.
nference used its artificial intelligence software to analyze the records within 30 days of administration of Mayo Clinic patients who had received any of the three vaccines.
Why It Matters: Overall, the study assessed 771,805 vaccinations, including 10 FDA-approved, non-COVID shots, spanning 266,094 Mayo patients and dating as far back as January 2017, and found no statistically significant differences in CVST rates for any of them.
Pfizer's Xeljanz Cuts Incidence Of Death, Respiratory Failure In COVID-19 Patients, Brazilian Study Shows.
Pfizer Inc (NYSE: PFE) said that its oral rheumatoid arthritis drug Xeljanz (tofacitinib) reduced death or respiratory failure in hospitalized COVID-19 patients with pneumonia in Brazil, meeting the study’s primary goal.
Results of the study, which tested the drug in 289 hospitalized adult patients with respiratory illness due to the infection, were published in the New England Journal of Medicine.
Incidence of death or respiratory failure was 18.1% for patients treated with the drug compared to.
What Happened: Results of the second interim analysis of CureVac’s international Phase 2b/3 study of its first-generation vaccine candidate showed vaccine efficacy of 47% against COVID-19 disease of any severity, the German company said in a statement